No connection

Search Results

GRAL vs LLY

GRAL
GRAIL, Inc.
BEARISH
Price
$45.63
Market Cap
$1.87B
Sector
Healthcare
AI Confidence
85%
LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
GRAL
--
LLY
41.7
Forward P/E
GRAL
-5.04
LLY
22.78
P/B Ratio
GRAL
0.71
LLY
32.33
P/S Ratio
GRAL
12.72
LLY
13.16
EV/EBITDA
GRAL
-2.71
LLY
27.08

Profitability

Gross Margin
GRAL
48.46%
LLY
83.04%
Operating Margin
GRAL
-285.37%
LLY
44.9%
Profit Margin
GRAL
-277.46%
LLY
31.67%
ROE
GRAL
-16.07%
LLY
101.16%
ROA
GRAL
-11.31%
LLY
19.41%

Growth

Revenue Growth
GRAL
14.0%
LLY
42.6%
Earnings Growth
GRAL
--
LLY
51.4%

Financial Health

Debt/Equity
GRAL
0.02
LLY
1.65
Current Ratio
GRAL
11.97
LLY
1.58
Quick Ratio
GRAL
11.58
LLY
0.78

Dividends

Dividend Yield
GRAL
--
LLY
0.68%
Payout Ratio
GRAL
0.0%
LLY
26.14%

AI Verdict

GRAL BEARISH

GRAL exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical operational instability. While the company maintains an exceptionally high current ratio (11.97) and low debt, these are offset by catastrophic profit margins (-277.46%) and a bearish technical trend. Despite consistent earnings beats relative to low expectations and a 'Buy' analyst consensus, heavy insider selling ($95.49M) suggests a lack of confidence from leadership.

Strengths
Extremely high liquidity with a current ratio of 11.97
Very low leverage (Debt/Equity of 0.02)
Positive gross margins (48.46%) indicating product viability
Risks
Critical operational health (Piotroski F-Score 1/9)
Severe negative profitability and operating margins
Aggressive insider selling with zero buy transactions
LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

GRAL vs LLY: Head-to-Head Comparison

This page compares GRAIL, Inc. (GRAL) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile